BioCentury
ARTICLE | Clinical News

Cethrin: Phase I/IIa ongoing

July 2, 2007 7:00 AM UTC

ALSE (formerly Boston Life Sciences Inc.) said FDA approved a protocol change for an ongoing open-label, dose-escalation, North American Phase I/IIa trial to increase the dose level of cethrin to 9 m...